Medicinal Products Law Passes, Outlook For Strong Growth Remains

BMI View: While certain aspects of Bulgaria's law on medicinal products in human medicine have negative implications for drugmakers operating in the country, we maintain the view that Bulgaria's pharmaceutical market looks set for high single-figure growth over the long term. The market's attractiveness is somewhat limited by its size and low per-capita expenditure, but BMI believes elevated growth rates, including demand for innovative medicines, makes the country an appealing target for multinational drugmakers.

To read the full article, please choose one of the following options: